In vitro and in vivo evaluation of Δ9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy

Martín-Banderas, Lucía; Muñoz-Rubio, Inmaculada; Prados, José; Álvarez-Fuentes, Josefa; Calderón-Montaño, José Manuel; López‐Lázaro, Miguel; Arias, José L.; Leiva, María C.; Holgado, M.A.; Fernández‐Arévalo, M.

doi:10.1016/j.ijpharm.2015.04.054

Cited by 48 publications

(32 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3A and B ). This control cells toxicity has been observed in similar studies using the same inmortalized cells 36 , 37 . In addition, our results contrast with those found in HT-29 colorectal cancer cells in which PTX-loaded tripalmitin NPs achieved rates of cell death similar to free PTX 15 although the avoidance of Cremophor in this formulation provided an advantage in itself.…”

Section: Resultssupporting

confidence: 83%

Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

Leiva

Ortíz

Contreras‐Cáceres

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells. Tripalm-NPs-PTX decreased PTX IC50 by as much as 40.5-fold in breast and 38.8-fold in lung cancer cells and Tripalm-NPs-PTX macelignan inhibited P-glycoprotein in resistant tumor cells. In addition, Tripalm-NPs-PTX significantly decreased the volume of breast and lung multicellular tumor spheroids that mimics in vivo tumor mass. Finally, Tripalm-NPs-PTX decreased the PTX IC50 of cancer stem cells (CSCs) derived from both lung and breast cancer cells (6.7- and 14.9-fold for MCF7 and A549 CSCs, respectively). These results offer a new PTX nanoformulation based on the use of tripalmitin which improves the antitumor activity of PTX and that may serve as an alternative PTX delivery system in breast and lung cancer treatment.

show abstract

Section: Resultssupporting

confidence: 83%

Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

Leiva

Ortíz

Contreras‐Cáceres

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In contrast, Zhu et al showed that Δ 9 -THC increased the tumorigenicity of 3LL lung cancer cells in allografted immunocompetent mice and demonstrated that CB2 mediated inhibition of anti-tumor lymphocyte activity was the primary mechanism for accelerated tumor growth (Zhu et al, 2000 ). Furthermore, these investigators and the Arevalo group found that Δ 9 -THC administration had no effect on tumor growth in xenografted immunodeficient mice (Zhu et al, 2000 ; Martin-Banderas et al, 2015 ). Stable analogs of AEA also showed differential effects on lung cancer progression in vivo .…”

Section: Lung Cancermentioning

confidence: 98%

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

et al. 2016

View full text Add to dashboard Cite

Cancer is the second leading cause of death in the United States with 1.7 million new cases estimated to be diagnosed in 2016. This disease remains a formidable clinical challenge and represents a substantial financial burden to the US health care system. Therefore, research and development of novel therapeutics for the treatment of cancer is of high priority. Cannabinoids and their derivatives have been utilized for their medicinal and therapeutic properties throughout history. Cannabinoid activity is regulated by the endocannabinoid system (ECS), which is comprised of cannabinoid receptors, transporters, and enzymes involved in cannabinoid synthesis and breakdown. More recently, cannabinoids have gained special attention for their role in cancer cell proliferation and death. However, many studies investigated these effects using in vitro models which may not adequately mimic tumor growth and metastasis. As such, this article aims to review study results which evaluated effects of cannabinoids from plant, synthetic and endogenous origins on cancer development in preclinical animal models and to examine the current standing of cannabinoids that are being tested in human cancer patients.

show abstract

“…The results suggested that PCL particles were an alternative delivery system for long-term cannabinoid administration [94]. Martín-Banderas et al produced Δ9-THC-loaded PLGA nanoparticles [114]. The nanoformulation was further improved by surface functionalization with CS and PEG, to optimize the pharmacokinetics.…”

Section: Anti-inflammatory Phytoconstituents and Their Nanoparticlmentioning

confidence: 99%

“…However, CS and PEG coatings decreased and increased, respectively, the Δ9-THC release kinetics. The safety of all PLGA-based formulations was confirmed by in vivo compatibility studies; moreover, protein adsorption tests suggested that PEGylation protected the phytodrug against immune processes [114]. Table 2 acts as a summary of synthesized nanosized delivery systems for phytocannabinoids.…”

Section: Anti-inflammatory Phytoconstituents and Their Nanoparticlmentioning

confidence: 99%

Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds

Conte¹,

Marturano

Peluso³

et al. 2017

IJMS

View full text Add to dashboard Cite

Phytocompounds have been used in medicine for decades owing to their potential in anti-inflammatory applications. However, major difficulties in achieving sustained delivery of phyto-based drugs are related to their low solubility and cell penetration, and high instability. To overcome these disadvantages, nanosized delivery technologies are currently in use for sustained and enhanced delivery of phyto-derived bioactive compounds in the pharmaceutical sector. This review focuses on the recent advances in nanocarrier-mediated drug delivery of bioactive molecules of plant origin in the field of anti-inflammatory research. In particular, special attention is paid to the relationship between structure and properties of the nanocarrier and phytodrug release behavior.

show abstract

In vitro and in vivo evaluation of Δ9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy

Cited by 48 publications

References 46 publications

Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds

Contact Info

Product

Resources

About